Can a custom vaccine train the body to fight ovarian cancer?

NCT ID NCT00799110

Terminated Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This phase 2 trial tests a personalized vaccine made from a patient's own immune cells fused with their tumor cells, given alongside GM-CSF injections and imiquimod cream. The goal is to see if this combination can trigger a stronger immune response against ovarian, fallopian tube, or primary peritoneal cancer. Researchers will also monitor side effects and any impact on the cancer itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A personalized vaccine made from a patient's own dendritic cells fused with their tumor cells, given with GM-CSF injections and imiquimod cream
What this could lead to: If it works, this approach could strengthen the immune system's ability to fight ovarian cancer and potentially slow or shrink the disease.
What could go wrong: This is a small, early-phase trial, so the vaccine may not produce a strong immune response or affect the cancer. Side effects from the vaccine or the immune boosters are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER OVARIAN CANCER PRIMARY PERITONEAL CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Brigham & Women's Hospital

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.